Inside Innovation

Proniras Corporation, a biotech company based in Seattle, raised $4.6 million in funding and is seeking nearly $8 million more, according to a recent SEC

Avalyn Pharma, AltPep, Viome Life Sciences and Parse Biosciences are among various Seattle startups that secured ample funding in 2023, despite tightening budgets, reduced venture

Neoleukin Therapeutics, a biotech company that spun out of the University of Washington in 2019, finalized its merger with Neurogene, a biotech firm based in

Seattle biotech startup Parse Biosciences received $50 million in funding from a Series C equity round. Capitalist firms including Soleus Capital, Marshall Wace and Bioeconomy

Seattle will be the site of a new Prenuvo clinic, a full-body imaging company from Silicon Valley specializing in MRI scans. The company’s full-body machine,

Redmond-based biotech company Systimmune has secured an exclusive license and collaboration agreement with Bristol Myers Squibb (BMS) to support the development of its solid tumor

Pfizer’s pending acquisition of Seattle-based biotech company Seagen closed on December 14th, according to an announcement from Pfizer. Amid the newly approved deal, Pfizer plans

AstraZeneca announced that it will pay up to $1.1 billion to acquire Seattle-based biotechnology company Icosavax. Spun out of the Institute for Protein Design at

A new biotech company called BrainChild Bio was created by Seattle Children’s Clinic. The company’s focus is a CAR T-cell therapy initiative aimed at treating

The Seattle Hub for Synthetic Biology (the Hub), a new biotech company specializing in self-monitoring cells, received $75 million to support its collaboration with University

Nadia Dac, Omeros Corporation’s chief commercial officer, was named one of the top 50 women leaders of Seattle by Women We Admire. Dac has nearly

Biotech company Absci, based in Vancouver, Washington, is teaming up with AstraZeneca to create antibody therapeutics to combat cancer. The deal is worth over $200